Pierfrancesco Veroux

Pierfrancesco Veroux


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2002 in Transplantation Proceedings
Verified
Journal Article
Closed access
PVPierfrancesco Veroux
Pierfrancesco Veroux
MVMassimiliano Veroux
Massimiliano Veroux
CPC Puliatti
C Puliatti
WMW Morale
W Morale
DCD Cappello
D Cappello
MMM Macarone
M Macarone

1 October 2021 in EuroIntervention
Verified
Journal Article
Open access
GCGiuliano Costa
Giuliano Costa
RVRoberto Valvo
Roberto Valvo
APAndrea Picci
Andrea Picci
ECEnrico Criscione
Enrico Criscione
CRClaudia Reddavid
Claudia Reddavid
MBMarco Barbanti
Marco Barbanti
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

29 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MVMassimiliano Veroux
Massimiliano Veroux
PSPaolo Scollo
Paolo Scollo
MGMartina Maria Giambra
Martina Maria Giambra
GRGiuseppe Roscitano
Giuseppe Roscitano
AGAlessia Giaquinta
Alessia Giaquinta
PVPierfrancesco Veroux
Pierfrancesco Veroux
Uterus transplantation (UTx) is currently the only available treatment for absolute uterine factor infertility. More than 90 uterus transplantations have been performed worldwide, mostly from living donors. Living-donor (LD) UTx is a challenging surgical procedure since it poses ethical issues, and it is a high-risk and invasive surgery with higher hysterectomy-related risks compared to conventional hysterectomy. A total of 59 living-donor hysterectomies have been reported in the literature, including 35 performed with a laparotomic approach, 20 with a robotic approach and 4 with a laparoscopic approach. The mean donor age was 45.6 ± 9.1 years, and 22 were unrelated with the recipients, 34 were emotionally related (27 mothers, 5 sisters, 2 mother’s sisters). The mean recipient age was 28.8 ± 4.5 years. Mayer–Rokitansky–Küster–Hauser syndrome was the most common indication for uterus transplant. Robotic living-donor hysterectomy had the longest operative time but resulted in a lower blood loss and postoperative stay compared to laparotomic and laparoscopic approaches. Twenty-nine births from LD-UTx have been reported, four after robotic living-donor hysterectomy and twenty-five after a laparotomic procedure. UTx is now an effective treatment for women with UFI. While living-donor UTx in some cases may be considered an experimental procedure, it offers the extraordinary possibility to give women the opportunity to have a pregnancy. Many efforts should be made to reduce the potential risks for donors, including the use of mini-invasive techniques, and the efficacy of UTx in the recipients, giving the potential harm of immunosuppression in a recipient of a non-life-saving organ.

7 October 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
MVMassimiliano Veroux
Massimiliano Veroux
IMInes Monte
Ines Monte
MRMargherita Stefania Rodolico
Margherita Stefania Rodolico
DCDaniela Corona
Daniela Corona
RBRita Bella
Rita Bella
OTon behalf of “Multidisciplinary Research Center for the diagnosis and treatment of Fabry Disease and for Organ Transplantation
on behalf of “Multidisciplinary Research Center for the diagnosis and treatment of Fabry Disease and for Organ Transplantation
Fabry disease (FD) is a rare cause of end-stage renal disease requiring kidney transplantation. Data on the incidence of unrecognized FD in kidney transplant recipients are scarce and probably underestimated. This study evaluated the incidence of FD in a population of kidney recipients, with a particular focus of the multidisciplinary approach for an early clinical assessment and therapeutic approach. Two hundred sixty-five kidney transplant recipients were screened with a genetic analysis for α-galactosidase A (GLA) mutation, with measurement of α-Gal A enzyme activity and Lyso Gb3 levels. Screening was also extended to relatives of affected patients. Seven patients (2.6%) had a GLA mutation. Two patients had a classic form of FD with Fabry nephropathy. Among the relatives, 15 subjects had a GLA mutation, and two had a Fabry nephropathy. The clinical and diagnostic assessment was completed after a median of 3.2 months, and mean time from diagnosis to treatment was 4.6 months. This study reported a high incidence of unrecognized GLA mutations in kidney transplant recipients. Evaluation and management by a multidisciplinary team allowed for an early diagnosis and treatment, and this would result in a delay in the progression of the disease and, finally, in better long-term outcomes.

1 July 2010 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
PVPierfrancesco Veroux
Pierfrancesco Veroux
GDG. D'ARrigo
G. D'ARrigo
MVMassimiliano Veroux
Massimiliano Veroux
AGA. Giaquinta
A. Giaquinta
ALA. Lomeo
A. Lomeo

30 May 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
DCDaniela Corona
Daniela Corona
BEBurcin Ekser
Burcin Ekser
RGRossella Gioco
Rossella Gioco
Massimo CarusoMassimo Caruso
Massimo Caruso
CSChiara Schipa
Chiara Schipa
MVMassimiliano Veroux
Massimiliano Veroux
Kidney transplantation is a well-established therapy for patients with end-stage renal disease. While a significant improvement of short-term results has been achieved in the short-term, similar results were not reported in the long-term. Heme-oxygenase (HO) is the rate-limiting enzyme in heme catabolism, converting heme to iron, carbon monoxide, and biliverdin. Heme-oxygenase overexpression may be observed in all phases of transplant processes, including brain death, recipient management, and acute and chronic rejection. HO induction has been proved to provide a significant reduction of inflammatory response and a reduction of ischemia and reperfusion injury in organ transplantation, as well as providing a reduction of incidence of acute rejection. In this review, we will summarize data on HO and kidney transplantation, suggesting possible clinical applications in the near future to improve the long-term outcomes.